Literature DB >> 15486069

Hepcidin is decreased in TFR2 hemochromatosis.

Elizabeta Nemeth1, Antonella Roetto, Giovanni Garozzo, Tomas Ganz, Clara Camaschella.   

Abstract

The hepatic peptide hepcidin is the key regulator of iron metabolism in mammals. Recent evidence indicates that certain forms of hereditary hemochromatosis are caused by hepcidin deficiency. Juvenile hemochromatosis is associated with hepcidin or hemojuvelin mutations, and these patients have low or absent urinary hepcidin. Patients with C282Y HFE hemochromatosis also have inappropriately low hepcidin levels for the degree of iron loading. The relationship between the hemochromatosis due to transferrin receptor 2 (TFR2) mutations and hepcidin was unknown. We measured urinary hepcidin levels in 10 patients homozygous for TFR2 mutations, all with increased transferrin saturation. Urinary hepcidin was low or undetectable in 8 of 10 cases irrespective of the previous phlebotomy treatments. The only 2 cases with normal hepcidin values had concomitant inflammatory conditions. Our data indicate that TFR2 is a modulator of hepcidin production in response to iron.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15486069     DOI: 10.1182/blood-2004-08-3042

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  142 in total

1.  Measurement of serum hepcidin-25 levels as a potential test for diagnosing hemochromatosis and related disorders.

Authors:  Yoshibumi Kaneko; Hiroaki Miyajima; Alberto Piperno; Naohisa Tomosugi; Hisao Hayashi; Natsuko Morotomi; Ken-ichi Tsuchida; Takaaki Ikeda; Akihisa Ishikawa; Yusuke Ota; Shinya Wakusawa; Kentaro Yoshioka; Satoshi Kono; Sara Pelucchi; Ai Hattori; Yasuaki Tatsumi; Toshihide Okada; Masakazu Yamagishi
Journal:  J Gastroenterol       Date:  2010-06-09       Impact factor: 7.527

Review 2.  Modulation of hepcidin as therapy for primary and secondary iron overload disorders: preclinical models and approaches.

Authors:  Paul J Schmidt; Mark D Fleming
Journal:  Hematol Oncol Clin North Am       Date:  2014-01-18       Impact factor: 3.722

Review 3.  The pathophysiology and pharmacology of hepcidin.

Authors:  Piotr Ruchala; Elizabeta Nemeth
Journal:  Trends Pharmacol Sci       Date:  2014-02-17       Impact factor: 14.819

Review 4.  A systems biology approach to iron metabolism.

Authors:  Julia Chifman; Reinhard Laubenbacher; Suzy V Torti
Journal:  Adv Exp Med Biol       Date:  2014       Impact factor: 2.622

5.  Of mice and men: the iron age.

Authors:  Sophie Vaulont; Dan-Qing Lou; Lydie Viatte; Axel Kahn
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

6.  A mouse model of juvenile hemochromatosis.

Authors:  Franklin W Huang; Jack L Pinkus; Geraldine S Pinkus; Mark D Fleming; Nancy C Andrews
Journal:  J Clin Invest       Date:  2005-08       Impact factor: 14.808

Review 7.  Is the iron regulatory hormone hepcidin a risk factor for alcoholic liver disease?

Authors:  Duygu Dee Harrison-Findik
Journal:  World J Gastroenterol       Date:  2009-03-14       Impact factor: 5.742

8.  Expression of hepcidin and other iron-related genes in type 3 hemochromatosis due to a novel mutation in transferrin receptor-2.

Authors:  Sara Pelucchi; Raffaella Mariani; Paola Trombini; Sabina Coletti; Matteo Pozzi; Valentina Paolini; Donatella Barisani; Alberto Piperno
Journal:  Haematologica       Date:  2009-01-14       Impact factor: 9.941

9.  Two BMP responsive elements, STAT, and bZIP/HNF4/COUP motifs of the hepcidin promoter are critical for BMP, SMAD1, and HJV responsiveness.

Authors:  Jaroslav Truksa; Pauline Lee; Ernest Beutler
Journal:  Blood       Date:  2008-11-07       Impact factor: 22.113

Review 10.  Regulation of iron absorption in hemoglobinopathies.

Authors:  Gideon Rechavi; Stefano Rivella
Journal:  Curr Mol Med       Date:  2008-11       Impact factor: 2.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.